SLN · Insider Trading
Silence Therapeutics Plc American Depository Share
Every open-market purchase and sale reported by SLN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-13 | Richard Ian Griffiths | 10%+ Owner | Sell | +5,484,320 deriv. | — |
| 2026-07-07 | Richard Ian Griffiths | 10%+ Owner | Sell | +1,544,374 deriv. | — |
| 2026-02-13 | Richard Ian Griffiths | 10%+ Owner | MIXED | +44,000 deriv. | — |
| 2026-01-06 | James Ede-Golightly | Director | A | +90,000 deriv. | — |
| 2026-01-06 | Timothy McInerney | Director | A | +90,000 deriv. | — |
| 2026-01-06 | Rhonda Lynette Hellums | Chief Financial Officer | A | +375,000 deriv. | — |
| 2026-01-06 | David Lemus | Director | A | +90,000 deriv. | — |
| 2026-01-06 | Steven J. Romano | EVP and Chief R&D Officer | A | +300,000 deriv. | — |
| 2025-12-22 | Iain Ross | Interim PEO | A | +900,000 deriv. | — |
| 2025-12-22 | James Ede-Golightly | Director | A | +90,000 deriv. | — |
| 2025-08-04 | Richard Ian Griffiths | 10%+ Owner | Buy | +18,376 deriv. | — |
| 2025-07-31 | Richard Ian Griffiths | 10%+ Owner | Buy | +23,482 deriv. | — |
| 2025-07-23 | Richard Ian Griffiths | 10%+ Owner | Buy | +25,345 deriv. | — |
| 2025-07-16 | Richard Ian Griffiths | 10%+ Owner | Buy | +71,293 deriv. | — |
| 2025-07-10 | Richard Ian Griffiths | 10%+ Owner | Buy | +62,457 deriv. | — |
| 2025-06-30 | Richard Ian Griffiths | 10%+ Owner | Buy | +110,474 deriv. | — |
| 2025-06-25 | Richard Ian Griffiths | 10%+ Owner | Buy | +82,606 deriv. | — |
| 2025-06-20 | Richard Ian Griffiths | 10%+ Owner | Buy | +70,448 deriv. | — |
| 2025-06-13 | Richard Ian Griffiths | 10%+ Owner | Buy | +39,305 deriv. | — |
| 2025-05-29 | Richard Ian Griffiths | 10%+ Owner | Buy | +85,838 deriv. | — |
| 2025-05-27 | Richard Ian Griffiths | 10%+ Owner | Buy | +36,361 deriv. | — |
| 2025-05-21 | Richard Ian Griffiths | 10%+ Owner | Buy | +79,023 deriv. | — |
| 2025-05-20 | Timothy McInerney | Director | A | +48,000 deriv. | — |
| 2025-05-15 | Richard Ian Griffiths | 10%+ Owner | Buy | +150,000 deriv. | — |
| 2025-05-08 | Richard Ian Griffiths | 10%+ Owner | Buy | +250,000 deriv. | — |
| 2025-05-02 | Richard Ian Griffiths | 10%+ Owner | Buy | +109,575 deriv. | — |
| 2025-04-30 | Richard Ian Griffiths | 10%+ Owner | Buy | +149,979 deriv. | — |
| 2025-04-28 | Richard Ian Griffiths | 10%+ Owner | Buy | +150,000 deriv. | — |
| 2025-04-24 | Richard Ian Griffiths | 10%+ Owner | Buy | +100,000 deriv. | — |
| 2025-04-22 | Richard Ian Griffiths | 10%+ Owner | Buy | +150,000 deriv. | — |
| 2025-04-15 | Richard Ian Griffiths | 10%+ Owner | Buy | +200,000 deriv. | — |
| 2025-04-01 | Richard Ian Griffiths | 10%+ Owner | Buy | +100,000 deriv. | — |
| 2025-03-31 | Richard Ian Griffiths | 10%+ Owner | Buy | +200,000 deriv. | — |
| 2025-03-06 | Richard Ian Griffiths | 10%+ Owner | Buy | +22,632 deriv. | — |
| 2025-02-25 | Richard Ian Griffiths | 10%+ Owner | Buy | +450,000 deriv. | — |
| 2025-01-06 | James Ede-Golightly | Director | A | +48,000 deriv. | — |
| 2025-01-06 | Iain Ross | Director | A | +90,000 deriv. | — |
| 2025-01-06 | Craig A Tooman | President and CEO | A | +900,000 deriv. | — |
| 2025-01-06 | David Lemus | Director | A | +48,000 deriv. | — |
| 2025-01-06 | Rhonda Lynette Hellums | Chief Financial Officer | A | +375,000 deriv. | — |
| 2025-01-06 | Steven J. Romano | EVP and Chief R&D Officer | A | +285,000 deriv. | — |
| 2025-01-06 | Michael H. Davidson | Director | A | +48,000 deriv. | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SLN quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.